SCHEMBL13282919

SCHEMBL13282919

CSc1nc2ccc(F)cc2c(=O)n1NC(=O)Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.55
RAB9A P51151 1/20 0.52
ALDH1A1 P00352 4/20 0.49
HTT P42858 2/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
LMNA P02545 3/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
DHFR P00374 3/20 0.43
MAPK14 Q16539 1/20 0.43
PLA2G2A P14555 1/20 0.43
CASR P41180 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3379725 0.93 NPSR1 (0.57) NPSR1RAB9AALDH1A1HTTCYP1A2
SCHEMBL3380657 0.88 NPSR1 (0.58) NPSR1RAB9AALDH1A1HTTCYP1A2
SCHEMBL13282992 0.85 NPSR1 (0.45) NPSR1RAB9AALDH1A1HTTCYP1A2
SCHEMBL13282879 0.82 ALDH1A1 (0.44) NPSR1RAB9AALDH1A1HTTCYP1A2
SCHEMBL3379765 0.82 NPSR1 (0.54) NPSR1RAB9AALDH1A1HTTCYP1A2
SCHEMBL3380682 0.82 NPSR1 (0.56) NPSR1RAB9AALDH1A1HTTCYP1A2
SCHEMBL13283038 0.81 NPSR1 (0.58) NPSR1RAB9AALDH1A1HTTCYP1A2
SCHEMBL13102235 0.81 MEN1 (0.48) NPSR1RAB9AALDH1A1HTTLMNA
SCHEMBL13282997 0.81 NPSR1 (0.58) NPSR1RAB9AALDH1A1HTTCYP1A2
SCHEMBL3378370 0.81 NPSR1 (0.55) NPSR1RAB9AALDH1A1HTTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS KCNQ1, KCNK17, KCNQ2 NPSR1 1722/4885RAB9A 560/4885ALDH1A1 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.